Determining the significance of MGUS

Giampaolo Merlini

doi:10.1182/blood-2013-12-539940

Determining the significance of MGUS

Giampaolo Merlini

IRCCS Fondazione Policlinico San Matteo

Research output: Contribution to journal › Article › peer-review

Abstract

In this issue of Blood, Turesson et al study the risk of progression of monoclonal gammopathy of undetermined significance (MGUS) to lymphoplasma cellular and myeloid malignancies in a large population, validating current risk factors and adding immunoparesis as a predictor of progression.

Original language	English
Pages (from-to)	305-307
Number of pages	3
Journal	Blood
Volume	123
Issue number	3
DOIs	https://doi.org/10.1182/blood-2013-12-539940
Publication status	Published - Jan 16 2014

ASJC Scopus subject areas

Hematology
Biochemistry
Cell Biology
Immunology

Access to Document

10.1182/blood-2013-12-539940

Fingerprint Dive into the research topics of 'Determining the significance of MGUS'. Together they form a unique fingerprint.

Cite this

@article{170990de245d44dd878336a238abb0f8,

title = "Determining the significance of MGUS",

abstract = "In this issue of Blood, Turesson et al study the risk of progression of monoclonal gammopathy of undetermined significance (MGUS) to lymphoplasma cellular and myeloid malignancies in a large population, validating current risk factors and adding immunoparesis as a predictor of progression.",

author = "Giampaolo Merlini",

year = "2014",

month = jan,

day = "16",

doi = "10.1182/blood-2013-12-539940",

language = "English",

volume = "123",

pages = "305--307",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "3",

}

TY - JOUR

T1 - Determining the significance of MGUS

AU - Merlini, Giampaolo

PY - 2014/1/16

Y1 - 2014/1/16

N2 - In this issue of Blood, Turesson et al study the risk of progression of monoclonal gammopathy of undetermined significance (MGUS) to lymphoplasma cellular and myeloid malignancies in a large population, validating current risk factors and adding immunoparesis as a predictor of progression.

AB - In this issue of Blood, Turesson et al study the risk of progression of monoclonal gammopathy of undetermined significance (MGUS) to lymphoplasma cellular and myeloid malignancies in a large population, validating current risk factors and adding immunoparesis as a predictor of progression.

UR - http://www.scopus.com/inward/record.url?scp=84893045216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893045216&partnerID=8YFLogxK

U2 - 10.1182/blood-2013-12-539940

DO - 10.1182/blood-2013-12-539940

M3 - Article

C2 - 24434993

AN - SCOPUS:84893045216

VL - 123

SP - 305

EP - 307

JO - Blood

JF - Blood

SN - 0006-4971

IS - 3

ER -